Liu, Heng-Jia http://orcid.org/0000-0001-9685-6572
Du, Heng
Khabibullin, Damir
Zarei, Mahsa
Wei, Kevin
Freeman, Gordon J. http://orcid.org/0000-0002-7210-5616
Kwiatkowski, David J. http://orcid.org/0000-0002-5668-5219
Henske, Elizabeth P. http://orcid.org/0000-0001-7978-6699
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-21-1-0223)
LAM Foundation (LAM0149C01-21)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (1U01HL131022-01)
Engles Family TSC/LAM Research Fund Lee Family Research Fund
Article History
Received: 1 September 2022
Accepted: 21 February 2023
First Online: 3 March 2023
Competing interests
: G.J.F. has patents/pending royalties on the PD-1/PD-L1 pathway from Roche, Merck MSD, Bristol-Myers-Squibb, Merck KGA, Boehringer-Ingelheim, AstraZeneca, Dako, Leica, Mayo Clinic, and Novartis. G.J.F. has a patent on RGMb in cancer immunotherapy. G.J.F. has served on advisory boards for Roche, Bristol-Myers-Squibb, Xios, Origimed, Triursus, iTeos, NextPoint, IgM, Jubilant, Trillium, GV20, IOME, and Geode. G.J.F. has equity in Nextpoint, Triursus, Xios, iTeos, IgM, Trillium, Invaria, GV20, and Geode. The remaining authors declare no other competing interests.